Molecular Cytogenetics Market By Product (Instruments, Consumables, Software and Services), By Technique (Comparative Genomic Hybridization, Fluorescence in Situ Hybridization, Others), By Application (Genetic Disorders , Cancer , Personalized Medicines, Others), By End User (Clinical and Research Laboratories, Pharmaceutical and Biotechnology Companies, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global molecular cytogenetics market was valued at $2,233.5 million in 2021, and is projected to reach $5,146.55 million by 2031, registering a CAGR of 8.7%.
Molecular cytogenetics includes the chromosome biology and the use of molecular cytogenetic methods in biology and medicine. These include the structural and functional establishment of the chromosome and nucleus, genome variation, expression, and evolution, chromosome abnormalities, and genomic variations in tumor genetics and medical genetics. The testing includes identifying a specific gene or gene locus (molecular) with direct visualization of the cells and chromosomes under a fluorescence microscope and is far from being outdated and is actively involved in up-to-date diagnostics and research.
According to National Center for Biotechnology Information (NCBI), an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. This prevalence of cancer diseases among all age groups owing to changes (mutations) to the DNA within cells, will lead to the increase in the demand for diagnostic techniques of molecular cytogenetics.
Furthermore, the growth of the molecular cytogenetics market is anticipated to be facilitated by the introduction of numerous cutting-edge diagnostic technologies by the biotechnology companies, an increase in demand for accurate diagnosis of serious cancer diseases, and the availability of interventional pathologist with the necessary training in developed economies.
In addition, advancements in molecular cytogenetics, increase in incidence of genetic disorders & cancer and rise in awareness & acceptance of personalized medicines, are some of the factors that are boosting the market growth. The development of the techniques including interphase fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), multicolor karyotyping, telomere FISH, primed in situ labelling (PRINS), and telomere FISH, have caused the expansion of the market. However, the market is expected to be significantly constrained in the near future by factors such as high cost associated with the procedure.
In addition, the use of molecular pathology in disease diagnosis, disease prevention, and treatment is now possible using the molecular cytogenetics. For instance, the development of the BioPrime Total Genomic Labeling System by the Thermo Fisher Scientific, which is a complete genomic DNA labeling system designed for use in array comparative genomic hybridization applications (aCGH) that allows for better call rates with precious samples.
The molecular cytogenetics market is segmented on the basis of product, technique, application, end user and region. By product, it is divided into instruments, consumables, and software & services. On the basis of technique, the market is segmented into comparative genomic hybridization, fluorescence in situ hybridization and others. Further, the comparative genomic hybridization segment is divided into array-based comparative genomic hybridization and standard comparative genomic hybridization. By application, the market is segmented into genetic disorders, cancer, personalized medicine and others. According to the end user, the market is segmented into clinical & research laboratories, pharmaceutical & biotechnology companies and others (academic research institutes, contract research organization [CRO]). Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in this report include Abbott Laboratories, Agilent Technologies Inc., Applied Spectral Imaging, Cyto Test Inc., Danaher Corporation (Cephied), Empire Genomics, LLC., Genial Genetic Solutions Ltd., Illumina, Inc., Perkinelmer, Inc., Sema4 Holdings Corp., Sysmex Corporation (Oxford Gene Technology) and Thermo Fisher Scientific Inc. and among others.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the molecular cytogenetics market analysis from 2021 to 2031 to identify the prevailing molecular cytogenetics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the molecular cytogenetics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global molecular cytogenetics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
Instruments
Consumables
Software and Services
By Technique
Comparative Genomic Hybridization
Type
Array-Based Comparative Genomic Hybridization
Standard Comparative Genomic Hybridization
Fluorescence in Situ Hybridization
Others
By Application
Genetic Disorders
Cancer
Personalized Medicines
Others
By End User
Pharmaceutical and Biotechnology Companies
Others
Clinical and Research Laboratories
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest Of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest Of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest Of LAMEA
Key Market Players
Abbott Laboratories
Agilent Technologies Inc.
Applied Spectral Imaging
Cyto Test Inc.
Danaher Corporation (Cephied)
Empire Genomics, LLC.
Genial Genetic Solutions Ltd.
Illumina, Inc.
PerkinElmer, Inc.
Sema4 Holdings Corp.
Sysmex Corporation (Oxford Gene Technology)
Thermo Fisher Scientific Inc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- 3.7.Patent Landscape
- CHAPTER 4: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Instruments
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Consumables
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Software and Services
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- CHAPTER 5: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Comparative Genomic Hybridization
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.2.4 Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
- 5.2.4.1 Array-Based Comparative Genomic Hybridization Market size and forecast, by region
- 5.2.4.2 Standard Comparative Genomic Hybridization Market size and forecast, by region
- 5.3 Fluorescence in Situ Hybridization
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Others
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- CHAPTER 6: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Genetic Disorders
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Cancer
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Personalized Medicines
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- 6.5 Others
- 6.5.1 Key market trends, growth factors and opportunities
- 6.5.2 Market size and forecast, by region
- 6.5.3 Market analysis by country
- CHAPTER 7: MOLECULAR CYTOGENETICS MARKET, BY END USER
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 Clinical and Research Laboratories
- 7.2.1 Key market trends, growth factors and opportunities
- 7.2.2 Market size and forecast, by region
- 7.2.3 Market analysis by country
- 7.3 Pharmaceutical and Biotechnology Companies
- 7.3.1 Key market trends, growth factors and opportunities
- 7.3.2 Market size and forecast, by region
- 7.3.3 Market analysis by country
- 7.4 Others
- 7.4.1 Key market trends, growth factors and opportunities
- 7.4.2 Market size and forecast, by region
- 7.4.3 Market analysis by country
- CHAPTER 8: MOLECULAR CYTOGENETICS MARKET, BY REGION
- 8.1 Overview
- 8.1.1 Market size and forecast
- 8.2 North America
- 8.2.1 Key trends and opportunities
- 8.2.2 North America Market size and forecast, by Product
- 8.2.3 North America Market size and forecast, by Technique
- 8.2.3.1 North America Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
- 8.2.4 North America Market size and forecast, by Application
- 8.2.5 North America Market size and forecast, by End User
- 8.2.6 North America Market size and forecast, by country
- 8.2.6.1 U.S.
- 8.2.6.1.1 Market size and forecast, by Product
- 8.2.6.1.2 Market size and forecast, by Technique
- 8.2.6.1.3 Market size and forecast, by Application
- 8.2.6.1.4 Market size and forecast, by End User
- 8.2.6.2 Canada
- 8.2.6.2.1 Market size and forecast, by Product
- 8.2.6.2.2 Market size and forecast, by Technique
- 8.2.6.2.3 Market size and forecast, by Application
- 8.2.6.2.4 Market size and forecast, by End User
- 8.2.6.3 Mexico
- 8.2.6.3.1 Market size and forecast, by Product
- 8.2.6.3.2 Market size and forecast, by Technique
- 8.2.6.3.3 Market size and forecast, by Application
- 8.2.6.3.4 Market size and forecast, by End User
- 8.3 Europe
- 8.3.1 Key trends and opportunities
- 8.3.2 Europe Market size and forecast, by Product
- 8.3.3 Europe Market size and forecast, by Technique
- 8.3.3.1 Europe Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
- 8.3.4 Europe Market size and forecast, by Application
- 8.3.5 Europe Market size and forecast, by End User
- 8.3.6 Europe Market size and forecast, by country
- 8.3.6.1 Germany
- 8.3.6.1.1 Market size and forecast, by Product
- 8.3.6.1.2 Market size and forecast, by Technique
- 8.3.6.1.3 Market size and forecast, by Application
- 8.3.6.1.4 Market size and forecast, by End User
- 8.3.6.2 France
- 8.3.6.2.1 Market size and forecast, by Product
- 8.3.6.2.2 Market size and forecast, by Technique
- 8.3.6.2.3 Market size and forecast, by Application
- 8.3.6.2.4 Market size and forecast, by End User
- 8.3.6.3 UK
- 8.3.6.3.1 Market size and forecast, by Product
- 8.3.6.3.2 Market size and forecast, by Technique
- 8.3.6.3.3 Market size and forecast, by Application
- 8.3.6.3.4 Market size and forecast, by End User
- 8.3.6.4 Italy
- 8.3.6.4.1 Market size and forecast, by Product
- 8.3.6.4.2 Market size and forecast, by Technique
- 8.3.6.4.3 Market size and forecast, by Application
- 8.3.6.4.4 Market size and forecast, by End User
- 8.3.6.5 Spain
- 8.3.6.5.1 Market size and forecast, by Product
- 8.3.6.5.2 Market size and forecast, by Technique
- 8.3.6.5.3 Market size and forecast, by Application
- 8.3.6.5.4 Market size and forecast, by End User
- 8.3.6.6 Rest of Europe
- 8.3.6.6.1 Market size and forecast, by Product
- 8.3.6.6.2 Market size and forecast, by Technique
- 8.3.6.6.3 Market size and forecast, by Application
- 8.3.6.6.4 Market size and forecast, by End User
- 8.4 Asia-Pacific
- 8.4.1 Key trends and opportunities
- 8.4.2 Asia-Pacific Market size and forecast, by Product
- 8.4.3 Asia-Pacific Market size and forecast, by Technique
- 8.4.3.1 Asia-Pacific Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
- 8.4.4 Asia-Pacific Market size and forecast, by Application
- 8.4.5 Asia-Pacific Market size and forecast, by End User
- 8.4.6 Asia-Pacific Market size and forecast, by country
- 8.4.6.1 Japan
- 8.4.6.1.1 Market size and forecast, by Product
- 8.4.6.1.2 Market size and forecast, by Technique
- 8.4.6.1.3 Market size and forecast, by Application
- 8.4.6.1.4 Market size and forecast, by End User
- 8.4.6.2 China
- 8.4.6.2.1 Market size and forecast, by Product
- 8.4.6.2.2 Market size and forecast, by Technique
- 8.4.6.2.3 Market size and forecast, by Application
- 8.4.6.2.4 Market size and forecast, by End User
- 8.4.6.3 Australia
- 8.4.6.3.1 Market size and forecast, by Product
- 8.4.6.3.2 Market size and forecast, by Technique
- 8.4.6.3.3 Market size and forecast, by Application
- 8.4.6.3.4 Market size and forecast, by End User
- 8.4.6.4 India
- 8.4.6.4.1 Market size and forecast, by Product
- 8.4.6.4.2 Market size and forecast, by Technique
- 8.4.6.4.3 Market size and forecast, by Application
- 8.4.6.4.4 Market size and forecast, by End User
- 8.4.6.5 South Korea
- 8.4.6.5.1 Market size and forecast, by Product
- 8.4.6.5.2 Market size and forecast, by Technique
- 8.4.6.5.3 Market size and forecast, by Application
- 8.4.6.5.4 Market size and forecast, by End User
- 8.4.6.6 Rest of Asia-Pacific
- 8.4.6.6.1 Market size and forecast, by Product
- 8.4.6.6.2 Market size and forecast, by Technique
- 8.4.6.6.3 Market size and forecast, by Application
- 8.4.6.6.4 Market size and forecast, by End User
- 8.5 LAMEA
- 8.5.1 Key trends and opportunities
- 8.5.2 LAMEA Market size and forecast, by Product
- 8.5.3 LAMEA Market size and forecast, by Technique
- 8.5.3.1 LAMEA Comparative Genomic Hybridization Molecular Cytogenetics Market by Type
- 8.5.4 LAMEA Market size and forecast, by Application
- 8.5.5 LAMEA Market size and forecast, by End User
- 8.5.6 LAMEA Market size and forecast, by country
- 8.5.6.1 Brazil
- 8.5.6.1.1 Market size and forecast, by Product
- 8.5.6.1.2 Market size and forecast, by Technique
- 8.5.6.1.3 Market size and forecast, by Application
- 8.5.6.1.4 Market size and forecast, by End User
- 8.5.6.2 Saudi Arabia
- 8.5.6.2.1 Market size and forecast, by Product
- 8.5.6.2.2 Market size and forecast, by Technique
- 8.5.6.2.3 Market size and forecast, by Application
- 8.5.6.2.4 Market size and forecast, by End User
- 8.5.6.3 South Africa
- 8.5.6.3.1 Market size and forecast, by Product
- 8.5.6.3.2 Market size and forecast, by Technique
- 8.5.6.3.3 Market size and forecast, by Application
- 8.5.6.3.4 Market size and forecast, by End User
- 8.5.6.4 Rest of LAMEA
- 8.5.6.4.1 Market size and forecast, by Product
- 8.5.6.4.2 Market size and forecast, by Technique
- 8.5.6.4.3 Market size and forecast, by Application
- 8.5.6.4.4 Market size and forecast, by End User
- CHAPTER 9: COMPANY LANDSCAPE
- 9.1. Introduction
- 9.2. Top winning strategies
- 9.3. Product Mapping of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Key developments
- CHAPTER 10: COMPANY PROFILES
- 10.1 Abbott Laboratories
- 10.1.1 Company overview
- 10.1.2 Company snapshot
- 10.1.3 Operating business segments
- 10.1.4 Product portfolio
- 10.1.5 Business performance
- 10.1.6 Key strategic moves and developments
- 10.2 Agilent Technologies Inc.
- 10.2.1 Company overview
- 10.2.2 Company snapshot
- 10.2.3 Operating business segments
- 10.2.4 Product portfolio
- 10.2.5 Business performance
- 10.2.6 Key strategic moves and developments
- 10.3 Applied Spectral Imaging
- 10.3.1 Company overview
- 10.3.2 Company snapshot
- 10.3.3 Operating business segments
- 10.3.4 Product portfolio
- 10.3.5 Business performance
- 10.3.6 Key strategic moves and developments
- 10.4 Cyto Test Inc.
- 10.4.1 Company overview
- 10.4.2 Company snapshot
- 10.4.3 Operating business segments
- 10.4.4 Product portfolio
- 10.4.5 Business performance
- 10.4.6 Key strategic moves and developments
- 10.5 Danaher Corporation (Cephied)
- 10.5.1 Company overview
- 10.5.2 Company snapshot
- 10.5.3 Operating business segments
- 10.5.4 Product portfolio
- 10.5.5 Business performance
- 10.5.6 Key strategic moves and developments
- 10.6 Empire Genomics, LLC.
- 10.6.1 Company overview
- 10.6.2 Company snapshot
- 10.6.3 Operating business segments
- 10.6.4 Product portfolio
- 10.6.5 Business performance
- 10.6.6 Key strategic moves and developments
- 10.7 Genial Genetic Solutions Ltd.
- 10.7.1 Company overview
- 10.7.2 Company snapshot
- 10.7.3 Operating business segments
- 10.7.4 Product portfolio
- 10.7.5 Business performance
- 10.7.6 Key strategic moves and developments
- 10.8 Illumina, Inc.
- 10.8.1 Company overview
- 10.8.2 Company snapshot
- 10.8.3 Operating business segments
- 10.8.4 Product portfolio
- 10.8.5 Business performance
- 10.8.6 Key strategic moves and developments
- 10.9 PerkinElmer, Inc.
- 10.9.1 Company overview
- 10.9.2 Company snapshot
- 10.9.3 Operating business segments
- 10.9.4 Product portfolio
- 10.9.5 Business performance
- 10.9.6 Key strategic moves and developments
- 10.10 Sema4 Holdings Corp.
- 10.10.1 Company overview
- 10.10.2 Company snapshot
- 10.10.3 Operating business segments
- 10.10.4 Product portfolio
- 10.10.5 Business performance
- 10.10.6 Key strategic moves and developments
- 10.11 Sysmex Corporation (Oxford Gene Technology)
- 10.11.1 Company overview
- 10.11.2 Company snapshot
- 10.11.3 Operating business segments
- 10.11.4 Product portfolio
- 10.11.5 Business performance
- 10.11.6 Key strategic moves and developments
- 10.12 Thermo Fisher Scientific Inc.
- 10.12.1 Company overview
- 10.12.2 Company snapshot
- 10.12.3 Operating business segments
- 10.12.4 Product portfolio
- 10.12.5 Business performance
- 10.12.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 2. MOLECULAR CYTOGENETICS MARKET, FOR INSTRUMENTS, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. MOLECULAR CYTOGENETICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. MOLECULAR CYTOGENETICS MARKET, FOR CONSUMABLES, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. MOLECULAR CYTOGENETICS MARKET FOR CONSUMABLES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. MOLECULAR CYTOGENETICS MARKET, FOR SOFTWARE AND SERVICES, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. MOLECULAR CYTOGENETICS MARKET FOR SOFTWARE AND SERVICES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 8. GLOBAL MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 9. MOLECULAR CYTOGENETICS MARKET, FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. MOLECULAR CYTOGENETICS MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 11. GLOBAL COMPARATIVE GENOMIC HYBRIDIZATION MOLECULAR CYTOGENETICS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 12. MOLECULAR CYTOGENETICS MARKET, FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 13. MOLECULAR CYTOGENETICS MARKET, FOR STANDARD COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. MOLECULAR CYTOGENETICS MARKET, FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 15. MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 16. MOLECULAR CYTOGENETICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 17. MOLECULAR CYTOGENETICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 18. GLOBAL MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 19. MOLECULAR CYTOGENETICS MARKET, FOR GENETIC DISORDERS , BY REGION, 2021-2031 ($MILLION)
- TABLE 20. MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS , BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 21. MOLECULAR CYTOGENETICS MARKET, FOR CANCER , BY REGION, 2021-2031 ($MILLION)
- TABLE 22. MOLECULAR CYTOGENETICS MARKET FOR CANCER , BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 23. MOLECULAR CYTOGENETICS MARKET, FOR PERSONALIZED MEDICINES, BY REGION, 2021-2031 ($MILLION)
- TABLE 24. MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 25. MOLECULAR CYTOGENETICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 26. MOLECULAR CYTOGENETICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 27. GLOBAL MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 28. MOLECULAR CYTOGENETICS MARKET, FOR CLINICAL AND RESEARCH LABORATORIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 29. MOLECULAR CYTOGENETICS MARKET FOR CLINICAL AND RESEARCH LABORATORIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 30. MOLECULAR CYTOGENETICS MARKET, FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 31. MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 32. MOLECULAR CYTOGENETICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 33. MOLECULAR CYTOGENETICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 34. MOLECULAR CYTOGENETICS MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 35. NORTH AMERICA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 36. NORTH AMERICA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 37. NORTH AMERICA COMPARATIVE GENOMIC HYBRIDIZATION MOLECULAR CYTOGENETICS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 38. NORTH AMERICA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 39. NORTH AMERICA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 40. NORTH AMERICA MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 41. U.S. MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 42. U.S. MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 43. U.S. MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 44. U.S. MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 45. CANADA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 46. CANADA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 47. CANADA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 48. CANADA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 49. MEXICO MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 50. MEXICO MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 51. MEXICO MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 52. MEXICO MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 53. EUROPE MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 54. EUROPE MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 55. EUROPE COMPARATIVE GENOMIC HYBRIDIZATION MOLECULAR CYTOGENETICS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 56. EUROPE MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 57. EUROPE MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 58. EUROPE MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 59. GERMANY MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 60. GERMANY MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 61. GERMANY MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 62. GERMANY MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 63. FRANCE MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 64. FRANCE MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 65. FRANCE MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 66. FRANCE MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 67. UK MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 68. UK MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 69. UK MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 70. UK MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 71. ITALY MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 72. ITALY MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 73. ITALY MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 74. ITALY MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 75. SPAIN MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 76. SPAIN MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 77. SPAIN MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 78. SPAIN MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 79. REST OF EUROPE MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 80. REST OF EUROPE MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 81. REST OF EUROPE MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 82. REST OF EUROPE MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 83. ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 84. ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 85. ASIA-PACIFIC COMPARATIVE GENOMIC HYBRIDIZATION MOLECULAR CYTOGENETICS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 86. ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 87. ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 88. ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 89. JAPAN MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 90. JAPAN MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 91. JAPAN MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 92. JAPAN MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 93. CHINA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 94. CHINA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 95. CHINA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 96. CHINA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 97. AUSTRALIA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 98. AUSTRALIA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 99. AUSTRALIA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 100. AUSTRALIA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 101. INDIA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 102. INDIA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 103. INDIA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 104. INDIA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 105. SOUTH KOREA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 106. SOUTH KOREA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 107. SOUTH KOREA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 108. SOUTH KOREA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 109. REST OF ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 110. REST OF ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 111. REST OF ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 112. REST OF ASIA-PACIFIC MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 113. LAMEA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 114. LAMEA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 115. LAMEA COMPARATIVE GENOMIC HYBRIDIZATION MOLECULAR CYTOGENETICS MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 116. LAMEA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 117. LAMEA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 118. LAMEA MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 119. BRAZIL MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 120. BRAZIL MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 121. BRAZIL MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 122. BRAZIL MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 123. SAUDI ARABIA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 124. SAUDI ARABIA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 125. SAUDI ARABIA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 126. SAUDI ARABIA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 127. SOUTH AFRICA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 128. SOUTH AFRICA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 129. SOUTH AFRICA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 130. SOUTH AFRICA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 131. REST OF LAMEA MOLECULAR CYTOGENETICS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 132. REST OF LAMEA MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 133. REST OF LAMEA MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 134. REST OF LAMEA MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 135.ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 136.ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 137.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 138.ABBOTT LABORATORIES: NET SALES,
- TABLE 139.ABBOTT LABORATORIES: KEY STRATERGIES
- TABLE 140.AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT
- TABLE 141.AGILENT TECHNOLOGIES INC.: OPERATING SEGMENTS
- TABLE 142.AGILENT TECHNOLOGIES INC.: PRODUCT PORTFOLIO
- TABLE 143.AGILENT TECHNOLOGIES INC.: NET SALES,
- TABLE 144.AGILENT TECHNOLOGIES INC.: KEY STRATERGIES
- TABLE 145.APPLIED SPECTRAL IMAGING: COMPANY SNAPSHOT
- TABLE 146.APPLIED SPECTRAL IMAGING: OPERATING SEGMENTS
- TABLE 147.APPLIED SPECTRAL IMAGING: PRODUCT PORTFOLIO
- TABLE 148.APPLIED SPECTRAL IMAGING: NET SALES,
- TABLE 149.APPLIED SPECTRAL IMAGING: KEY STRATERGIES
- TABLE 150.CYTO TEST INC.: COMPANY SNAPSHOT
- TABLE 151.CYTO TEST INC.: OPERATING SEGMENTS
- TABLE 152.CYTO TEST INC.: PRODUCT PORTFOLIO
- TABLE 153.CYTO TEST INC.: NET SALES,
- TABLE 154.CYTO TEST INC.: KEY STRATERGIES
- TABLE 155.DANAHER CORPORATION (CEPHIED): COMPANY SNAPSHOT
- TABLE 156.DANAHER CORPORATION (CEPHIED): OPERATING SEGMENTS
- TABLE 157.DANAHER CORPORATION (CEPHIED): PRODUCT PORTFOLIO
- TABLE 158.DANAHER CORPORATION (CEPHIED): NET SALES,
- TABLE 159.DANAHER CORPORATION (CEPHIED): KEY STRATERGIES
- TABLE 160.EMPIRE GENOMICS, LLC.: COMPANY SNAPSHOT
- TABLE 161.EMPIRE GENOMICS, LLC.: OPERATING SEGMENTS
- TABLE 162.EMPIRE GENOMICS, LLC.: PRODUCT PORTFOLIO
- TABLE 163.EMPIRE GENOMICS, LLC.: NET SALES,
- TABLE 164.EMPIRE GENOMICS, LLC.: KEY STRATERGIES
- TABLE 165.GENIAL GENETIC SOLUTIONS LTD.: COMPANY SNAPSHOT
- TABLE 166.GENIAL GENETIC SOLUTIONS LTD.: OPERATING SEGMENTS
- TABLE 167.GENIAL GENETIC SOLUTIONS LTD.: PRODUCT PORTFOLIO
- TABLE 168.GENIAL GENETIC SOLUTIONS LTD.: NET SALES,
- TABLE 169.GENIAL GENETIC SOLUTIONS LTD.: KEY STRATERGIES
- TABLE 170.ILLUMINA, INC.: COMPANY SNAPSHOT
- TABLE 171.ILLUMINA, INC.: OPERATING SEGMENTS
- TABLE 172.ILLUMINA, INC.: PRODUCT PORTFOLIO
- TABLE 173.ILLUMINA, INC.: NET SALES,
- TABLE 174.ILLUMINA, INC.: KEY STRATERGIES
- TABLE 175.PERKINELMER, INC.: COMPANY SNAPSHOT
- TABLE 176.PERKINELMER, INC.: OPERATING SEGMENTS
- TABLE 177.PERKINELMER, INC.: PRODUCT PORTFOLIO
- TABLE 178.PERKINELMER, INC.: NET SALES,
- TABLE 179.PERKINELMER, INC.: KEY STRATERGIES
- TABLE 180.SEMA4 HOLDINGS CORP.: COMPANY SNAPSHOT
- TABLE 181.SEMA4 HOLDINGS CORP.: OPERATING SEGMENTS
- TABLE 182.SEMA4 HOLDINGS CORP.: PRODUCT PORTFOLIO
- TABLE 183.SEMA4 HOLDINGS CORP.: NET SALES,
- TABLE 184.SEMA4 HOLDINGS CORP.: KEY STRATERGIES
- TABLE 185.SYSMEX CORPORATION (OXFORD GENE TECHNOLOGY): COMPANY SNAPSHOT
- TABLE 186.SYSMEX CORPORATION (OXFORD GENE TECHNOLOGY): OPERATING SEGMENTS
- TABLE 187.SYSMEX CORPORATION (OXFORD GENE TECHNOLOGY): PRODUCT PORTFOLIO
- TABLE 188.SYSMEX CORPORATION (OXFORD GENE TECHNOLOGY): NET SALES,
- TABLE 189.SYSMEX CORPORATION (OXFORD GENE TECHNOLOGY): KEY STRATERGIES
- TABLE 190.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
- TABLE 191.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
- TABLE 192.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
- TABLE 193.THERMO FISHER SCIENTIFIC INC.: NET SALES,
- TABLE 194.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.MOLECULAR CYTOGENETICS MARKET SEGMENTATION
- FIGURE 2.MOLECULAR CYTOGENETICS MARKET,2021-2031
- FIGURE 3.MOLECULAR CYTOGENETICS MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.MOLECULAR CYTOGENETICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.PATENT ANALYSIS BY COMPANY
- FIGURE 13.PATENT ANALYSIS BY COUNTRY
- FIGURE 14.MOLECULAR CYTOGENETICS MARKET,BY PRODUCT,2021(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF INSTRUMENTS MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CONSUMABLES MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF SOFTWARE AND SERVICES MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
- FIGURE 18.MOLECULAR CYTOGENETICS MARKET,BY TECHNIQUE,2021(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF COMPARATIVE GENOMIC HYBRIDIZATION MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF FLUORESCENCE IN SITU HYBRIDIZATION MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
- FIGURE 22.MOLECULAR CYTOGENETICS MARKET,BY APPLICATION,2021(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF GENETIC DISORDERS MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF CANCER MOLECULAR CYTOGENETICS MARKET,2021-2031(%)
- FIGURE 25.COMPARATIVE SH
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook